About Ovoca Bio

Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing Orenetide (BP-101), a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of Orenetide, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD. In March 2020, Orenetide became a fully owned program of Ovoca Bio.

Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.

Our Vision & Approach

Ovoca Bio’s vision is to become a leader in the research and development of, and commercial partner of choice for, novel medicines in areas of high unmet need that affect women.

The Company has filed for approval for the marketing of Orenetide in Russia and has commenced development of the drug for major global markets, with special focus on the US and Europe.

Ovoca Bio will consider opportunities to license commercialisation rights and/or collaborate with global pharmaceutical companies, regional partners or other qualified potential partners where they would accelerate the availability of current plus future product candidates to patients in need.

Ovoca Bio owns a patent portfolio that provides broad effective protection of its technology and lead product candidate. The Company intends to continue to leverage this patent portfolio and selectively add to it, to develop and commercialise its initial product candidate and potentially future ones.

European-based biopharmaceutical company with a focus on women’s health

Currently developing a novel synthetic peptide (Orenetide) for treatment of women with hypoactive sexual desire disorder (HSDD)

€13.6 million in cash and liquid assets to support drug development activities company with a focus on women’s health

Experienced team and top advisors to deliver on corporate goals

Our Team

Kirill Golovanov

Chief Executive & Interim Chairman

Christopher Wiltshire

Chief Business Officer

Dr. Daniil Nemenov

SVP, Clinical Development & Operations

Dr. Mikhail Lomonosov

VP, Research & IP

Dr. Alexey Matskevich

VP Preclinical

Dr. Eduard Benetskiy

VP, CMC

Dmitriy Nikitashenko

VP Finance

Valeria Kozlova

Director of Finance

Darina Bendas

Corporate Lawyer

Sofia Bachevskaya

Executive Assistant

Board of Directors

Kirill Golovanov

Chief Executive & Interim Chairman

Christopher Wiltshire

Executive Director

Romulo Colindres

Non-Executive Director

Timothy McCutcheon

Non-Executive Director

Leonid Skoptsov

Non-Executive Director

Expert Panel

Anita Clayton

HSDD Expert

Annamaria Giraldi

HSDD Expert

Sheryl Kingsberg

HSDD Expert

Rossella Nappi

HSDD Expert

Stephen Stahl

HSDD Expert